Coronavirus: age cap in Oxford vaccine trials casts doubt over results
AstraZeneca failed to disclose that under-55s made up test group in which jab was most effective

Oxford University and AstraZeneca are facing questions over their promising vaccine trial results after health officials revealed that key information about the ages of the test subjects was omitted.
During the Phase 3 trial, one group of test subjects was inoculated with two doses of the vaccine, spaced a month apart, while a second group was administered with a half-dose followed by a full one. In the first group, the protection rate was found to be 62%, but data from the second group showed that the vaccine was effective 90% of the time.
The reason for the wide discrepency has puzzled scientists. But they may now have their answer, after researcher Moncef Slaoui, who is spearheading the US’s vaccine distribution programme, told reporters that the age of participants in the second group “was capped at 55”, Bloomberg reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
No age breakdown was given in the reporting of the results, which have been cast into doubt over the omission of the most at-risk age demographics.
Former Pfizer research and development president Geoffrey Porges researchers “said he thought it was unlikely the AstraZeneca jab would get approval in the US after the company ‘tried to embellish their results’ by highlighting higher efficacy in a ‘relatively small subset of subjects in the study’”, the Financial Times reports.
Meanwhile, David Salisbury, an associate fellow of the global health programme at Chatham House, told The Telegraph: “You’ve taken two studies for which different doses were used and come up with a composite that doesn’t represent either of the doses. I think many people are having trouble with that.”
And the admission earlier this week by AstraZeneca that the half-dose was administered by error during the trials will add to “questions about whether the vaccine’s apparently spectacular efficacy will hold up under additional testing”, says The New York Times - which suggests that AstraZeneca’s “spotty disclosures have eroded confidence” in the jab.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
5 tips for maintaining your gut microbiome's health
The Week Recommends A healthy gut is all the rage in wellness circles
-
Trump's super-charged pardon push raises eyebrows and concerns
IN THE SPOTLIGHT Never shy about using his pardon ability for political leverage, Trump's spate of amnesty announcements suggests the White House is taking things to a new level
-
Elon Musk departs Trump administration
speed read The former DOGE head says he is ending his government work to spend more time on his companies
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
RFK Jr.: A new plan for sabotaging vaccines
Feature The Health Secretary announced changes to vaccine testing and asks Americans to 'do your own research'
-
Unraveling autism: RFK Jr.'s vow to find a root cause
Feature RFK Jr. has vowed to find the root cause of the 'autism epidemic' in months. Scientists have doubts.
-
The sneaking rise of whooping cough
Under the Radar The measles outbreak isn't the only one to worry about
-
Five years on: How Covid changed everything
Feature We seem to have collectively forgotten Covid’s horrors, but they have completely reshaped politics
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
-
How close are we to a norovirus vaccine?
Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year